← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Thetis Pharmaceuticals, Llc
Deep River, CT
$12,144,612
Total funding
6
Grants
Funding over time
peak $2.7M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,144,612 · 6
By mechanism
R44$11,850,890 · 5
R43$293,722 · 1
Investigators at Thetis Pharmaceuticals, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis$1,982,861
R44 · FY2020 · DK
Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer$1,725,203
R44 · FY2025 · CA
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$1,396,059
R44 · FY2018 · DK
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$1,196,452
R44 · FY2019 · DK
Development of TP-317 in Ulcerative Colitis$999,696
R44 · FY2025 · DK
Development of TP-317 in Ulcerative Colitis$999,624
R44 · FY2024 · DK
Development of TP-317 in Ulcerative Colitis$997,635
R44 · FY2023 · DK
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$571,983
R44 · FY2019 · DK
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$498,366
R44 · FY2020 · DK
Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer$398,404
R44 · FY2023 · CA
Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS)$299,561
R44 · FY2021 · AI
Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis$295,609
R44 · FY2019 · DK
Development of TP-317 for the Treatment of Eosinophilic Esophagitis$293,722
R43 · FY2019 · AI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$205,992
R44 · FY2017 · DK
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$205,144
R44 · FY2018 · DK
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$78,301
R44 · FY2018 · DK